AGR2 and breast cancer: The results showed that after 20 years of follow-up, only 26% of patients with AGR2 positive cancer survived, while the survival rate of patients with AGR2 negative cancer was 96%, and the median survival time was significantly different, 68 months and more than 216 months respectively (p<0.0001), indicating that the presence of AGR2 in primary tumors is a possible prognostic indicator of poor prognosis in patients with breast cancer.